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Research
Breast cancer is the second leading cancer-
related cause of death among women in the 
United States (American Cancer Society 2008). 
Previous epidemiologic and experimental inves-
tigations suggest that poly  cyclic aromatic hydro-
carbons (PAHs) may be associated with breast 
cancer (Bonner et al. 2005; el-Bayoumy et al. 
1995; Gammon et al. 2002b, 2004b; Rundle 
et al. 2000). However, despite strongly positive 
associations in animal models and some evi-
dence of a positive association in humans, the 
carcinogenicity of these chemical compounds 
on the human breast remains unclear.
PAHs are ubiquitous environmen-
tal pollu  tants formed by incomplete com-
bustion of organic material (Samanta et al. 
2002). These chemicals have estrogenic prop-
erties (Santodonato 1997), are known car-
cinogens in humans (Samanta et al. 2002), 
and cause mammary tumors in laboratory 
animals (el-Bayoumy et al. 1995; Hecht 
2002). Exposure to PAHs in the general 
population occurs primarily through charred, 
smoked, and broiled foods; leafy vegetables 
(Phillips 1999); wood- and coal-burning 
stoves (Lewis et al. 1999); air pollution (Lioy 
and Greenberg 1990); and tobacco smoke 
(Besaratinia et al. 2002). PAH–DNA adducts 
(Gammon et al. 2004b), lifetime intake of 
grilled/smoked meat (Steck et al. 2007), and 
long-term passive smoking—but not current 
or former active smoking (Gammon et al. 
2004a)—have been associated with breast 
cancer in our study population.
Cigarette smoke is associated with 
PAH–DNA adducts in human lymphocytes 
(Shantakumar et al. 2005), and the PAH 
benzo[a]pyrene (B[a]P) from cigarette smoke 
induces neoplastic transformation of human 
breast epithelial cells (Russo et al. 2002). 
However, smoking has been inconsistently 
linked to breast cancer in epidemiologic 
research, with more consistently positive find-
ings reported for long-term passive smoking 
and among genetically susceptible subgroups 
(Ambrosone et al. 2008; Terry and Goodman 
2006; Terry and Rohan 2002).
PAHs are formed on the surface of “well-
done” meat (Kazerouni et al. 2001), but epi-
demiologic studies examining meat intake 
or doneness have yielded inconclusive results 
(Holmes et al. 2003; Zheng et al. 1998). 
These studies have primarily focused on recent 
dietary habits, whereas lifetime intake may be 
more rele  vant for carcinogenesis. Steck et al. 
(2007) observed a positive association between 
lifetime intake of grilled and smoked meat and 
breast cancer among post  menopausal women 
[middle vs. lowest tertile of intake, odds ratio 
(OR) = 1.47; 95% confidence interval (CI), 
1.11–1.95; highest vs. lowest tertile of intake, 
OR = 1.47; 95% CI, 1.12–1.92)]. 
PAHs are metabolized through acti-
vation and detoxification pathways. When 
PAH exposure is high or detoxification is 
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Ba c k g r o u n d: Previous studies have suggested that polycyclic aromatic hydrocarbons (PAHs) 
may be associated with breast cancer. However, the carcinogenicity of PAHs on the human breast 
remains unclear. Certain carcinogens may be associated with specific mutation patterns in the p53 
tumor suppressor gene, thereby contributing information about disease etiology.
oBjectives: We hypothesized that associations of PAH-related exposures with breast cancer would 
differ according to tumor p53 mutation status, effect, type, and number.
Me t h o d s : We examined this possibility in a population-based case–control study using polytomous 
logistic regression. As previously reported, 151 p53 mutations among 859 tumors were identified 
using Surveyor nuclease and confirmed by sequencing.
re s u l t s: We found that participants with p53 mutations were less likely to be exposed to PAHs 
(assessed by smoking status in 859 cases and 1,556 controls, grilled/smoked meat intake in 822 
cases and 1,475 controls, and PAH–DNA adducts in peripheral mononuclear cells in 487 cases and 
941 controls) than participants without p53 mutations. For example, active and passive smoking 
was associated with p53 mutation–negative [odds ratio (OR) = 1.55; 95% confidence interval (CI), 
1.11–2.15] but not p53 mutation–positive (OR = 0.77; 95% CI, 0.43–1.38) cancer (ratio of the 
ORs = 0.50, p < 0.05). However, frameshift mutations, mutation number, G:C→A:T transitions at 
CpG sites, and insertions/deletions were consistently elevated among exposed subjects.
co n c l u s i o n s: These findings suggest that PAHs may be associated with specific breast tumor p53 
mutation subgroups rather than with overall p53 mutations and may also be related to breast cancer 
through mechanisms other than p53 mutation.
key w o r d s : breast cancer, p53 mutation, p53 over  expression, PAH, polycylic aromatic hydro-
carbons. Environ Health Perspect 118:511–518 (2010).  doi:10.1289/ehp.0901233 [Online 
18 November 2009]Mordukhovich et al.
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insufficient, PAH–DNA adducts form, includ-
ing in breast tissue (Gammon and Santella 
2008; Santella 1999). Adducts persist when 
repair mechanisms are inadequate (Braithwaite 
et al. 1999). Therefore, PAH–DNA adducts 
reflect both exposure to PAHs and host 
response—which differs because of variation 
in metabolism and/or DNA repair capacity 
between individuals—and are consistently 
associated with breast cancer in epidemiologic 
research (Gammon and Santella 2008).
The p53 protein is a transcription factor 
that regulates cell proliferation, differentia-
tion, apoptosis, and DNA repair and therefore 
plays an important role in normal cell func-
tion and neoplastic transformation (Levine 
1997). Certain carcinogens may be associated 
with specific mutation patterns in the p53 
tumor suppressor gene, and these characteris-
tic patterns of DNA damage may contribute 
information about disease etiology by lending 
biologic support to exposure–disease asso-
ciations and by helping to evaluate potential 
mechanisms of carcinogenesis (Greenblatt 
et al. 1994). Smoking has been associated 
with breast tumor p53 mutational spectra 
(Conway et al. 2002). We hypothesized that 
associations between PAH-related exposures 
and breast cancer would differ according to 
tumor p53 mutation status, effect, type, and 
number and we investigated this possibility 
using data from a population-based study.
Materials and Methods
Study population. Study subjects were par-
ticipants from the Long Island Breast Cancer 
Study Project (LIBCSP), details of which 
have been published previously (Gammon 
et al. 2002a). Briefly, the LIBCSP is a 
  population-based case–control study con-
ducted among English-speaking women 
20–98 years of age residing in Nassau and 
Suffolk counties in Long Island, New York. 
Cases were newly diagnosed with a first pri-
mary in situ or invasive breast cancer between 
1996 and 1997, and were identified by rapid 
case ascertainment through contact with local 
pathology departments. Controls with no his-
tory of breast cancer were randomly selected 
from the same two counties using random 
digit dialing for women < 65 years of age and 
by Health Care Finance Administration ros-
ters for women > 65 years of age. Controls 
were frequency matched to the expected age 
distribution of cases by 5-year age group. 
A total of 1,508 cases and 1,556 controls 
(82.1% and 62.7%, respectively, of all eligible 
subjects) completed the interview.
Questionnaire assessment of PAH expo­
sures. Trained interviewers completed in-
home questionnaires with cases and controls. 
Questionnaire topics included reproductive 
history, annual household income, alcohol 
intake, race, education, active and passive ciga-
rette smoking, lifetime dietary consumption 
of grilled and smoked foods, and other life-
style factors. Ninety-eight percent of cases and 
98% of controls completed a self-administered 
modified Block food frequency questionnaire 
(Block et al. 1986). These assessments were 
used to estimate lifetime intake of grilled and 
smoked meat, active and passive smoking, and 
daily intakes of B[a]P from meat and total 
energy using previously described methods 
(Gammon et al. 2004a; Steck et al. 2007). 
PAH–DNA adducts. Seventy-three per-
cent of cases and 73% of controls donated a 
blood sample at the interview (Gammon et al. 
2002a). DNA extracted from blood samples 
was used to assess PAH–DNA adduct lev-
els in whole blood by competitive enzyme-
linked immunosorbent assay (Gammon et al. 
2002b). The antibody used in this analysis 
recognizes PAH diol epoxide adducts that 
form at the N2 position of guanine.
p53 mutation analysis. Archived paraffin-
embedded tumor tissue was obtained from 
participating hospitals for 67% of case partici-
pants. DNA was successfully extracted from 
tumor tissue for 859 women, and mutations 
were detected in exons 5–8 of p53 through 
a multi  step process (Rossner et al. 2008). 
Briefly, the samples were amplified using poly-
merase chain reaction (PCR), and the Surveyor 
Mutation Detection Kit (Transgenomic, 
Omaha, NE, USA) was used as a screen-
ing method for detection of p53 mutations. 
Samples screening positive for potential muta-
tions were selected for confirmation and iden-
tification of mutations by PCR amplification 
and sequencing using an ABI 3100 capillary 
sequencer (Applied Biosystems Inc., Foster 
City, CA, USA). Surveyor nuclease shows 
some single-base mismatch cutting preference, 
although this disadvantage may be amelio-
rated by formation of alternate hetero  duplex 
mismatches (Qiu et al. 2004). As previously 
reported by Rossner et al. (2008), we identi-
fied a total of 151 p53 mutations among 859 
tumors, with 15 tumors harboring multiple 
mutations. In total, 15% of tumors contained 
one or more p53 mutations, 83% of which 
were point mutations and 17% of which were 
insertions/deletions.
p53 protein overexpression by immuno  histo­
chemistry. A total of 859 cases with available 
tumor tissue were evaluated for p53 protein 
expression by immunohisto  chemical staining 
Table 1. Distribution of p53 mutations by PAH-related exposures among LIBCSP case participants [n (%)].
Cigarette smoking history 
(n = 859)
Grilled and smoked meat 
intakea (n = 822)
Detectable PAH–DNA 
adducts (n = 487)
Mutation Ever Never High Low Yes No
Point mutations
Transitions
G:C→A:T at CpG 23 (29.1)  12 (16.7) 22 (28.2) 12 (17.1) 16 (27.1) 5 (23.8)
G:C→A:T at non-CpG 19 (24.1) 27 (37.5) 19 (24.4) 27 (38.6) 17 (28.8) 7 (33.3)
A:T→G:C 7 (8.9) 8 (11.1) 6 (7.7) 9 (12.9) 7 (11.9) 3 (14.3)
Transversions
G:C→T:A 5 (6.3) 12 (16.7) 9 (11.5) 6 (8.6) 5 (8.5) 1 (4.8)
G:C→C:G 5 (6.3) 1 (1.4) 4 (5.1) 2 (2.9) 1 (1.7) 1 (4.8)
A:T→T:A 3 (3.8) 2 (2.8) 2 (2.6) 3 (4.3) 1 (1.7) 2 (9.5)
A:T→C:G 0 (0) 1 (1.4) 0 (0) 1 (1.4) 0 (0) 0 (0)
Insertions or deletions 17 (21.5) 9 (12.5) 16 (20.5) 10 (14.3) 12 (20.3) 2 (9.5)
Base change
C→T at CpG 13 (21.0)  6 (9.5) 12 (19.4) 6 (10.0) 11 (23.4) 2 (10.5)
G→A at CpG 10 (16.1)  6 (9.5) 10 (16.1) 6 (10.0) 5 (10.6) 3 (15.8)
C→T at non-CpG 11 (17.7)  20 (31.8) 15 (24.2) 16 (26.7) 12 (25.5) 4 (21.1)
G→A at non-CpG 8 (12.9) 7 (11.1) 4 (6.5) 11 (18.3) 5 (10.6) 3 (15.8)
T→C 3 (4.8) 5 (7.9) 3 (4.8) 5 (8.3) 3 (6.4) 1 (5.3)
A→G 4 (6.5) 3 (4.8) 3 (4.8) 4 (6.7) 4 (8.5) 2 (10.5)
G→T 1 (1.6) 11 (17.5) 6 (9.7) 5 (8.3) 2 (4.3) 1 (5.3)
C→A 4 (6.5) 1 (1.6) 3 (4.8) 1 (1.7) 3 (6.4) 0 (0)
G→C 3 (4.8) 1 (1.6) 3 (4.8) 1 (1.7) 0 (0) 1 (5.3)
C→G 2 (3.2) 0 (0) 1 (1.6) 1 (1.7) 1 (2.1) 0 (0)
T→A 1 (1.6) 2 (3.2) 0 (0) 3 (5.0) 1 (2.1) 1 (5.3)
A→T 2 (3.2) 0 (0) 2 (3.2) 0 (0) 0 (0) 1 (5.3)
T→G 0 (0) 1 (1.6) 0 (0) 1 (1.7) 0 (0) 0 (0)
Mutation effect
Missense 38 (48.1)  42 (58.3) 41 (52.6) 36 (51.4) 23 (39.0)  18 (85.7)
Nonsense 8 (10.1) 8 (11.1) 7 (9.0) 9 (12.9) 6 (10.2) 1 (4.8)
Silent 16 (20.3)  13 (18.1) 14 (18.0) 15 (21.4) 18 (30.5)  0 (0)
Frameshift 17 (21.5) 9 (12.5) 16 (20.5) 10 (14.3) 12 (20.3)  2 (9.5)
No. of mutations 79 72 78 70 59 21
Tumors with mutations 66 (13.8) 62 (16.4) 63 (13.2) 62 (17.9) 47 (13.0)  18 (14.4)
Tumors with no mutations 414 (86.3)  317 (83.6) 413 (86.8)  284 (82.1) 315 (87.0)  107 (85.6)
Total no. of tumors 480 379 476 346 362 125
aLifetime intake of grilled and smoked meat is dichotomized based on median lifetime servings among controls 
(median = 4,160 servings). PAH, p53 mutations, and breast cancer risk
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using p53 mouse monoclonal anti  body clone 
DO-1 (Immunotech, Inc., Westbrook, ME, 
USA) at 1:5 dilution (Rossner et al. 2008). We 
evaluated nuclear staining by a semiquantita-
tive scoring system for intensity and percentage 
of positive nuclei. Tumors were considered 
positive if the staining had an intensity score 
of moderate or strong, if both study patholo-
gists considered them positive, and if at least 
10% of cells showed evidence of p53 protein 
expression. Previously published results from 
the LIBCSP show p53 over  expression in 36% 
of tumor samples (Rossner et al. 2008).
Statistical methods. We used polytomous 
logistic regression (Hosmer and Lemeshow 
1989) to estimate ORs and 95% CIs for asso-
ciations between breast cancer categorized by 
p53 tumor mutation subtype and smoking, 
intake of PAH food sources, and PAH–DNA 
adducts. We evaluated whether results for 
p53 mutation–negative and p53 mutation–
positive tumors differed statistically by calcu-
lating ratios of the ORs for the two outcomes 
(Schlesselman 1982). Polytomous logistic 
regression (Hosmer and Lemeshow 1989) 
was also used to estimate the ORs and 95% 
CIs for associations between breast cancer 
categorized by tumor p53 protein expression 
status and these same PAH-related factors. 
Because cases and controls were frequency 
matched by 5-year age group, we adjusted all 
statistical models for age group at reference. 
We performed additional analyses to examine 
associations of active smoking, grilled and 
smoked meat intake, and a combined meas-
ure of these factors with p53 mutation status, 
type, and effect using referent groups consist-
ing of never smokers with low lifetime grilled 
and smoked meat intake.
We defined current smokers as women 
who smoked within 12 months of the refer-
ence date. Former smokers stopped smoking 
> 12 months before this date, and passive 
smokers were women who reported ever liv-
ing with an active smoker (Gammon et al. 
2004a). We categorized lifetime intake 
of grilled and smoked meat relative to the 
median intake of 4,160 lifetime servings 
among controls (Steck et al. 2007). Daily 
intake of B[a]P from meat was categorized 
relative to the median intake of 0.42 ng/day   
(Steck et al. 2007). PAH–DNA adducts were 
categorized as detectable or non  detectable; 
for analytical purposes, we categorized sam-
ples with < 15% inhibition as non  detectable 
(Gammon et al. 2002b).
We identified potential confounders by a 
thorough review of the relevant literature and 
analysis of causal diagrams (Shrier and Platt 
2008). For PAH–DNA adducts, potential 
confounders were age at menarche, income, 
smoking status, and grilled and smoked meat 
intake. For dietary PAH intake, potential 
confounders were income, race, and energy 
intake. For smoking, potential confounders 
were income, alcohol intake, and education. 
We evaluated confounding by these covariates 
using backward selection with a 10% change 
in estimate criterion. In addition to adjust-
ment for 5-year age group, we adjusted final 
models for daily alcohol intake when looking 
at smoking and age at menarche when look-
ing at PAH–DNA adducts.
When examining associations with p53 
mutation status, participants were cases and 
controls with complete information regarding 
the exposure of interest and mutation status. As 
previously reported, the distribution of known 
and suspected breast cancer risk factors did 
not vary substantially between cases with and 
without available tumor tissue for p53 muta-
tion detection and p53 over  expression analysis 
(Rossner et al. 2008). Final sample sizes 
included 487 cases and 941 controls when 
examining PAH–DNA adducts, 859 cases 
and 1,556 controls for smoking status, and 
822 cases and 1,475 controls for meat intake. 
Inclusion criteria and sample sizes were similar 
when examining associations with p53 protein 
expression status.
Results
The distribution of p53 mutations by smoking 
history, grilled and smoked meat intake, and 
PAH–DNA adducts is presented in Table 1, 
and associations between PAH-related expo-
sures and p53 mutation status are presented 
in Table 2. p53 mutation–negative breast can-
cer was positively associated with detectable 
adducts (OR = 1.33; 95% CI, 1.02–1.73), 
Table 2. Associations between PAH-related exposures and the risk of breast cancer subtype as defined 
by p53 mutation status in the LIBCSP.a 
OR (95% CI)
Mutation status Cases/controls (n) Age-adjusted  Multivariate-adjusted
PAH–DNA adducts (detectable vs. nondetectable)
p53+ breast cancer 65/941 1.16 (0.66–2.04) 1.28 (0.71–2.31)
p53– breast cancer 422/941 1.34 (1.03–1.75) 1.33 (1.02–1.73)
Ratio of the ORs (p53+ vs. p53–) 0.86 (0.48–1.55) 0.96 (0.52–1.78)
Ever active smoking versus never active smoking
p53+ breast cancer 128/1,556 0.90 (0.62–1.30) 0.96 (0.66–1.39)
p53– breast cancer 731/1,556 1.11 (0.92–1.32) 1.09 (0.91–1.31)
Ratio of the ORs (p53+ vs. p53–) 0.82 (0.56–1.19) 0.88 (0.60–1.29)
Current active smoking versus never active smoking
p53+ breast cancer 80/989 0.80 (0.46–1.40) 0.87 (0.50–1.54)
p53– breast cancer 468/989 1.22 (0.96–1.56) 1.21 (0.94–1.55)
Ratio of the ORs (p53+ vs. p53–) 0.66 (0.37–1.17) 0.72 (0.40–1.29)
Past active smoking versus never active smoking
p53+ breast cancer 110/1,262 0.97 (0.65–1.44) 1.03 (0.69–1.55)
p53– breast cancer 580/1,262 1.06 (0.86–1.29) 1.05 (0.85–1.29)
Ratio of the ORs (p53+ vs. p53–) 0.91 (0.60–1.39) 0.99 (0.65–1.51)
Both active and passive smoking versus never passive or active smoking
p53+ breast cancer 68/875 0.71 (0.40–1.25) 0.77 (0.43–1.38)
p53– breast cancer 417/875 1.58 (1.14–2.18) 1.55 (1.11–2.15)
Ratio of the ORs (p53+ vs. p53–) 0.45 (0.24–0.82) 0.50 (0.27–0.93)
Active smoking only versus never passive or active smoking
p53+ breast cancer 35/328 1.14 (0.55–2.38) 1.23 (0.58–2.62)
p53– breast cancer 129/328 1.33 (0.86–2.04) 1.44 (0.93–2.24)
Ratio of the ORs (p53+ vs. p53–) 0.86 (0.39–1.87) 0.86 (0.39–1.90)
Ever passive smoking only versus never passive or active smoking
p53+ breast cancer 61/681 0.90 (0.50–1.61) 0.94 (0.52–1.68)
p53– breast cancer 306/681 1.38 (0.99–1.91) 1.38 (0.99–1.91)
Ratio of the ORs (p53+ vs. p53–) 0.65 (0.35–1.21) 0.68 (0.37–1.27)
Ever passively exposed to spouse versus never passively exposed to spouse
p53+ breast cancer 93/1,228 1.64 (1.03–2.60) 1.64 (1.03–2.61)
p53– breast cancer 602/1,228 1.25 (1.01–1.54) 1.25 (1.01–1.54)
Ratio of the ORs (p53+ vs. p53–) 1.31 (0.81–2.12) 1.32 (0.82–2.13)
Lifetime intake of smoked/grilled meat (high vs. low)b
p53+ breast cancer 125/1,475 1.08 (0.74–1.57) 1.08 (0.74–1.57)
p53– breast cancer 697/1,475 1.51 (1.25–1.82) 1.51 (1.25–1.82)
Ratio of the ORs (p53+ vs. p53–) 0.72 (0.48–1.06) 0.72 (0.48–1.06)
Total B[a]Ps from meat (high intake vs. low intake)c
p53+ breast cancer 124/1,473 1.28 (0.88–1.87) 1.28 (0.88–1.87)
p53– breast cancer 700/1,473 1.04 (0.86–1.25) 1.04 (0.86–1.25)
Ratio of the ORs (p53+ vs. p53–) 1.24 (0.84–1.83) 1.24 (0.84–1.83)
aIn addition to adjustment for age group, final models were adjusted for daily alcohol intake when examining smoking 
exposure and age at menarche when examining PAH–DNA adducts. Ratios of the ORs [OR for the association between 
exposure and p53-positive (p53+) breast cancer divided by OR for the association between exposure and p53-negative 
(p53–) breast cancer] were calculated as indicators of hetero  geneity of effects across groups. bLifetime intake of grilled 
and smoked meat is dichotomized based on median lifetime servings among controls (median, 4,160 servings). cDaily 
intake of B[a]Ps from meat is dichotomized based on median daily intake among controls (median, 0.42 ng/day). Mordukhovich et al.
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active and passive smoking (OR = 1.55; 
95% CI, 1.11–2.15), passive smoking from 
a spouse (OR = 1.25; 95% CI, 1.01–1.54), 
and high lifetime intake of grilled and smoked 
meat (OR = 1.51; 95% CI, 1.25–1.82). Effect 
estimates for all PAH-related exposures were 
elevated above the null for p53 mutation– 
negative cancer.
In contrast, many PAH-related expo-
sures were inversely associated with p53 
mutation–positive cancer (which primar-
ily comprised mis  sense mutations, but 
also included silent, non  sense, and frame-
shift mutations), and nearly all effect esti-
mates for p53 mutation–positive cancer for 
a given exposure were lower than the cor-
responding effect estimate for p53 muta-
tion–negative cancer (Table 2). Calculating 
ratios of the ORs (OR for the associa-
tion between exposure and p53 mutation– 
positive breast cancer divided by OR for the 
association between exposure and p53 muta-
tion–negative breast cancer) as an indicator 
of hetero  geneity of ORs across groups yielded 
statistically significant differences when exam-
ining active and passive smoking exposure 
[p53 mutation–positive cancer: OR = 1.55 
(95% CI, 1.11–2.15); p53 mutation– 
negative cancer: OR = 0.77 (95% CI, 0.43–
1.38); ratio of the ORs, 0.50 (95% CI, 
0.27–0.93)]. When we defined p53 status 
by protein expression status, we found no 
substantial hetero  geneity in the ORs for the 
associations between PAH-related exposures 
and p53-positive cancer and the correspond-
ing PAH exposures and p53-negative breast 
cancer [all p-values > 0.05 for the ratios of 
the ORs; see Supplemental Material, Table 3 
(doi:10.1289/ehp.0901233)].
Associations between PAH-related expo-
sures and selected p53 mutation types are 
presented in Table 3. We were unable to 
statistically evaluate relations for all muta-
tion types because of small numbers of certain 
mutations. We found consistently elevated 
associations between PAH-related exposures 
and G:C→A:T transitions at CpG sites as 
well as insertions/deletions. PAH-related 
exposures showed different directions of 
association with G:C→A:T transitions at 
non-CpG sites (Table 3), A:T→G:C transi-
tions, and G:C→T:A transversions (data not 
shown). PAH exposures were also inconsis-
tently related to p53 missense, nonsense, and 
silent mutations (Table 4). Frameshift muta-
tions were consistently associated with PAH-
related exposures, and these associations were 
strongest for PAH–DNA adducts. Few effect 
estimates for mutation type or effect reached 
statistical significance.
Table 5 shows relations between PAH-
related exposures and the number of tumor 
p53 mutations. We found that many PAH-
related exposures were associated with higher 
mutation number. For example, for detectable 
PAH–DNA adducts, ORs were 1.19 (95% CI, 
0.63–2.25) for one mutation, 1.87 (95% CI, 
0.38–9.20) for two mutations, and 2.15 (95% 
CI, 0.59–7.83) for three mutations relative to 
control participants, and ORs for high daily 
intake of B[a]Ps from meat were 1.17 (95% 
CI, 0.79–1.74) for one mutation, 1.79 (95% 
CI, 0.64–5.04) for two mutations, and 8.04 
(95% CI, 2.29–28.27) for three mutations.
We also examined associations of p53 
mutation status with active smoking and life-
time intake of grilled and smoked meat using 
referent groups consisting of never smokers 
with low intake of grilled and smoked meat. 
Use of this approach strengthened associa-
tions between PAH-related factors and p53 
  mutation–negative cancer, whereas associations 
with p53 mutation–positive cancer were essen-
tially unchanged [see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901233)]. In these 
analyses, p53 mutation–negative cancer was 
associated with smoking history (ever vs. never; 
OR = 1.31; 95% CI, 1.03–1.67), current 
smoking (OR = 1.43; 95% CI, 1.06–1.93), 
and lifetime intake of grilled and smoked meat 
(OR = 1.61; 95% CI, 1.27–2.05).
Relations between PAH-related exposures 
and G:C→A:T transitions at CpG sites, inser-
tions/deletions, and frameshift mutations 
were also strengthened by using the alterna-
tive referent groups. For example, examin-
ing associations between current smoking and 
insertions/deletions and between grilled and 
smoked meat intake and G:C→A:T transi-
tions at CpG sites yielded ORs of 3.06 (95% 
CI, 0.87–10.77) and 2.68 (95% CI, 0.89–
8.09), respectively [see Supplemental Material, 
Table 2 (doi:10.1289/ehp.0901233)]. We did 
not examine mutation number, A:T→G:C 
transitions, or G:C→T:A transversions due 
to low numbers of subjects with these muta-
tions. Results were not altered substantially for 
missense, nonsense, and silent mutations (data 
not shown). Comparing current smokers who 
had high lifetime intake of grilled and smoked 
meat with never smokers who had low intake 
of grilled and smoked meat yielded ORs of 
1.53 (95% CI, 1.07–2.20) for p53 mutation–
negative cancer, 4.24 (95% CI, 1.00–17.94) 
for G:C→A:T transitions at CpG sites, 4.49 
(95% CI, 1.05–19.25) for insertions/deletions, 
and 4.43 (95% CI, 1.04–18.98) for frameshift 
mutations.
Table 3. Associations between PAH-related exposures and the risk of breast cancer subtype as defined 
by p53 mutation type in the LIBCSP.a
OR (95% CI)
Mutation type Cases/controls (n) Age adjusted  Multivariate adjusted
G:C→A:T at CpG transitions
PAH–DNA adducts
Nondetectable 5/293 1.0 1.0
Detectable 16/648 1.51 (0.55–4.19) 1.53 (0.55–4.23)
Smoking status
Never 12/698 1.0 1.0
Former 16/564 1.60 (0.74–3.44) 1.65 (0.76–3.58)
Current 6/291 1.33 (0.49–3.67) 1.53 (0.55–4.27)
Grilled and smoked meatb
Low lifetime intake 12/739 1.0 1.0
High lifetime intake 21/736 1.69 (0.82–3.52) 1.69 (0.82–3.52)
G:C→A:T at non-CpG transitions
PAH–DNA adducts
Nondetectable 6/293 1.0 1.0
Detectable 15/648 1.10 (0.42–2.89) 1.09 (0.41–2.85)
Smoking status
Never 24/698 1.0 1.0
Former 14/564 0.73 (0.37–1.44) 0.80 (0.40–1.58)
Current 4/291 0.44 (0.15–1.29) 0.51 (0.17–1.52)
Grilled and smoked meat
Low intake 25/739 1.0 1.0
High intake 17/736 0.72 (0.38–1.37) 0.72 (0.38–1.37)
Insertions/deletions
PAH–DNA adducts
Nondetectable 2/293 1.0 1.0
Detectable 12/648 2.64 (0.58–11.91) 4.77 (0.63–36.25)
Smoking status
Never 9/698 1.0 1.0
Former 10/564 1.45 (0.58–3.65) 1.44 (0.56–3.69)
Current 7/291 2.11 (0.75–5.95) 2.41 (0.85–6.85)
Grilled and smoked meat
Low intake 10/739 1.0 1.0
High intake 16/736 1.68 (0.74–3.78) 1.68 (0.74–3.78)
aIn addition to adjustment for age group, final models were adjusted for daily alcohol intake when examining smoking 
exposure and age at menarche when examining PAH–DNA adducts. bLifetime intake of grilled and smoked meat is 
dichotomized based on median lifetime servings among controls (median, 4,160 servings). PAH, p53 mutations, and breast cancer risk
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Discussion
In this population-based analysis, we found 
that participants with breast tumor p53 muta-
tions were less likely to be exposed to PAH-
related sources than were participants with 
p53 mutation–negative cancer. However, 
frameshift mutations and number of muta-
tions were consistently elevated in exposed 
subjects, and tumors of women exposed to 
PAH-related sources showed a pattern of 
increased G:C→A:T transitions at CpG 
sites and insertions/deletions. Associations of 
PAH-related exposures with p53 mutation 
status, type, and effect were strengthened by 
minimizing PAH exposure in referent groups.
This is the first study to examine associa-
tions of dietary PAH intake, PAH–DNA 
adducts, and passive smoking with breast 
tumor p53 mutations. It is the third study to 
examine associations between active smoking 
and breast cancer p53 mutations, and has a 
larger sample size than the previous investiga-
tions (Conway et al. 2002; Van Emburgh et al. 
2008). Few studies have looked at relations 
between exogenous exposures and p53 muta-
tions in breast cancer, although such research 
has potential to provide insights regarding 
breast cancer etiology.
We found a relatively low prevalence 
of p53 mutations (15%) among our par-
ticipants, which is consistent with the wide 
range reported in the literature (11–35%) 
(Goldman and Shields 1998; Tennis et al. 
2006; Van Emburgh et al. 2008). This varia-
tion across studies may be due to differences 
between study populations, such as differences 
in distribution of age and race (Bowen et al. 
2006; Klauber-DeMore 2005). Methodologic 
errors in mutation detection may also have 
contributed to the modest mutation preva-
lence. However, we selected a method previ-
ously shown to have a high sensitivity (Qiu 
et al. 2004) and that has been used successfully 
in various applications, including detection of 
p53 mutations in hematologic malignancies 
(Mitani et al. 2007).
Immunohistochemical staining estimates 
p53 protein expression and is widely used as 
a proxy measure for detection of p53 muta-
tion status. However, the sensitivity of this 
method relative to mutation analysis is < 75% 
for breast cancer (Lacroix et al. 2006), and 
immuno  histochemistry is subject to a num-
ber of methodologic limitations (Hall and 
McCluggage 2006; McCabe et al. 2005). 
We detected over  expression in 36% of tumor 
samples (Rossner et al. 2008), which is con-
sistent with the range reported in the litera-
ture (30–40%) (Erdem et al. 2005; Iwase 
et al. 2001), but we did not find evidence of 
hetero  geneity in the ORs for the associations 
between PAH-related exposures and p53- 
positive cancer as defined by protein expression 
status and the corresponding PAH exposures 
and p53-negative breast cancer. This is con-
sistent with the results of one study of smok-
ing and p53 over  expression (Furberg et al. 
2002), and inconsistent with two other studies 
that noted an association between smoking 
and p53-positive breast cancer among younger 
women (Gammon et al. 1999; van der Kooy 
et al. 1996). Potential explanations for the dis-
crepant findings across investigations include 
inability to identify specific p53 mutational 
subtypes when using immuno  histochemistry 
as a proxy, differences in metabolic activation 
and detoxification of PAHs between study 
populations, and chance findings.
Conway et al. (2002) found that current 
smokers were more likely and former smokers 
were less likely than never smokers to have p53 
mutation–positive breast cancer. In contrast, 
we found that both current and former smok-
ers were less likely than never smokers to have 
p53 mutation–positive cancer. Another epide-
miologic study found positive, non  significant 
associations between smoking history and p53 
mutation prevalence (Van Emburgh et al. 
2008). However, the number of p53 mutation–
positive cases (n = 34, mutation prevalence 
= 11%) was substantially smaller than in our 
study (n = 128, mutation prevalence = 15%) or 
in the study by Conway et al. (2002; n = 108, 
mutation preva  lence = 24%), and the results 
appeared to be unstable. Reasons potentially 
under  lying inconsistent results between studies 
include differences in age and race distributions 
and in metabolism and detoxification of PAHs 
Table 4. Associations between PAH-related exposures and the risk of breast cancer subtype as defined 
by p53 mutation effect in the LIBCSP.a
OR (95% CI)
Mutation effect Cases/controls (n) Age adjusted Multivariate adjusted
Missense mutations
PAH–DNA adducts
Nondetectable 15/293 1.0 1.0
Detectable 20/648 0.62 (0.31–1.24) 0.67 (0.33–1.36)
Active smoking status
Never 37/698 1.0 1.0
Former 26/564 0.87 (0.52–1.47) 0.92 (0.54–1.56)
Current 7/291 0.51 (0.22–1.18) 0.53 (0.23–1.24)
Grilled/smoked meatb
Low lifetime intake 33/739 1.0 1.0
High lifetime intake 34/736 1.09 (0.66–1.80) 1.09 (0.66–1.80)
Nonsense mutations
PAH–DNA adducts
Nondetectable 1/293 1.0 1.0
Detectable 6/648 2.57 (0.31–21.47) 2.60 (0.31–21.94)
Active smoking status
Never 8/698 1.0 1.0
Former 7/564 1.05 (0.37–2.94) 1.21 (0.42–3.48)
Current 1/291 0.39 (0.05–3.28) 0.42 (0.05–3.56)
Grilled/smoked meat
Low intake 9/739 1.0 1.0
High intake 7/736 0.84 (0.30–2.33) 0.84 (0.30–2.33)
Silent mutations
PAH–DNA adducts
Nondetectable 0/293 1.0 1.0
Detectable 15/648 — —
Active smoking status
Never 11/698 1.0 1.0
Former 9/564 1.01 (0.41–2.48) 1.17 (0.47–2.90)
Current 4/291 1.15 (0.35–3.78) 1.37 (0.42–4.54)
Grilled/smoked meat
Low intake 15/739 1.0 1.0
High intake 9/736 0.65 (0.28–1.53) 0.65 (0.28–1.53)
Frameshift mutations
PAH–DNA adducts
Nondetectable 2/293 1.0 1.0
Detectable 12/648 2.62 (0.58–11.80) 4.85 (0.62–37.75)
Active smoking status
Never 9/698 1.0 1.0
Former 10/564 1.44 (0.57–3.63) 1.43 (0.56–3.66)
Current 7/291 2.11 (0.75–5.96) 2.40 (0.84–6.85)
Grilled/smoked meat
Low intake 10/739 1.0 1.0
High intake 16/736 1.68 (0.75–3.79) 1.68 (0.75–3.79)
aIn addition to adjustment for age group, final models were adjusted for daily alcohol intake when examining smoking 
exposure and age at menarche when examining PAH–DNA adducts. bLifetime intake of grilled and smoked meat is 
dichotomized based on median lifetime servings among controls (median, 4,160 servings). Mordukhovich et al.
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between study populations, varying defini-
tions of current smoking status, methodologic 
differences in mutation analysis, and chance 
findings.
The elevated associations between PAH-
related exposures and p53 mutation–  negative 
cancer may indicate that PAH-related factors 
are related to breast cancer through mecha-
nisms other than p53 mutation. Grilled 
and smoked meat and tobacco smoke con-
tain carcinogens other than PAHs, and 
PAH–DNA adducts or increased oxidative 
stress may lead to mutations in genes other 
than p53. Induction of DNA repair could 
also contribute to decreased mutation levels 
among women exposed to PAHs (Wei et al. 
2000). In vitro and in vivo investigations indi-
cate that repair is important in determining 
mutation patterns (Greenblatt et al. 1994). 
Furthermore, the fact that p53 mutation pat-
terns in tobacco-associated cancers show sur-
prising variation is thought to be due at least 
partly to differences in DNA repair between 
cancer sites (Greenblatt et al. 1994). We 
found evidence of statistical heterogeneity in 
the ORs between p53 mutation–positive and 
p53 mutation–negative cancer when look-
ing at exposure to both active and passive 
smoking. Associations between other PAH-
related exposures and breast cancer did not 
differ statistically between mutation status 
subtypes, possibly due to insufficient power 
to detect such differences. Inverse associations 
between PAH exposures and p53 mutation–
positive cancer may be due to random varia-
tion around the null.
PAH-related exposures have been 
shown to increase both frameshift and base 
substitution mutations (Adonis and Gil 
2000), and specific mutation effects may have 
etiologic associations. Relations of PAH expo-
sures with nonsense and silent mutations were 
inconsistent in our study. Results for p53 mis-
sense mutations were inconsistent as well, 
despite a larger sample size, with smoking and 
detectable adducts showing inverse associa-
tions and dietary PAH intake showing a posi-
tive associa  tion with missense mutations. It 
is plausible that different PAH-related expo-
sures could lead to differing mutation effects, 
although this inconsistency may also be due 
to chance. Frameshift mutations were consis-
tently elevated in exposed subjects, especially 
when looking at adducts and a combined 
measure of smoking and intake of grilled and 
smoked meat. PAHs induce frameshift muta-
tions through adduct-induced deformation of 
the DNA helix (Greenblatt et al. 1994).
Participants with PAH-related exposures 
exhibited a fairly consistent mutational spec-
trum, characterized by increased proportions 
of insertions/deletions and G:C→A:T tran-
sitions at CpG sites. We found inconsistent 
results regarding G:C→A:T transversions and 
G:C→A:T transitions at non-CpG sites. This 
is in contrast to a previous study that reported 
that smokers showed an increased proportion 
of breast tumor G:C→T:A transversions and 
found some suggestion of decreased G:C→A:T 
transitions at CpG sites (Conway et al. 2002).
Previous research has suggested that 
the p53 mutational spectrum of breast can-
cer includes high proportions of G:C→T:A 
transversions, G:C→A:T transitions at CpG 
sites, and insertions/deletions (Biggs et al. 
1993; Goldman and Shields 1998; Greenblatt 
et al. 1994). The latter two mutation types 
are thought to result from endogenous pro-
cesses (Greenblatt et al. 1994). However, it 
is possible that certain carcinogens produce 
a mutational spectrum similar to that due to 
endogenous processes (Biggs et al. 1993). For 
example, although benzo[a]pyrene diol epox-
ide adducts have been strongly associated with 
G→T transversions in vitro (Eisenstadt et al. 
1982; Ruggeri et al. 1993), G→A transitions 
occur as the predominant mutation in vivo 
in some contexts because of influences of the 
local environment (Shukla et al. 1997). PAHs 
have been associated with transitions at G:C 
base pairs (Harris 1991), and transitions and 
frameshifts may be induced by PAH–DNA 
adducts (Greenblatt et al. 1994). PAHs may 
also cause DNA damage by generating reac-
tive oxygen species, an endogenous mutagen 
(Singh et al. 2007). Moreover, it is very plau-
sible that some carcinogens influence the rate 
of accumulation of mutations without alter-
ing the pattern (Biggs et al. 1993). The latter 
hypothesis is supported by our finding that 
likelihood of PAH exposure increases with 
tumor p53 mutation number.
Table 5. Associations between PAH-related exposures and the number of tumor p53 mutations relative to 
control participants in the LIBCSP.a
OR (95% CI)
No. of mutations Cases/controls (n) Age adjusted Multivariate adjusted
PAH–DNA adducts (detectable vs. nondetectable)
1 55/941 1.06 (0.58–1.94) 1.19 (0.63–2.25)
2  10/941 1.85 (0.38–9.01) 1.87 (0.38–9.20)
3  15/941 2.10 (0.58–7.58) 2.15 (0.59–7.83)
Ever active smoking vs. never active smoking
1  113/1,556 0.89 (0.61–1.32) 0.94 (0.63–1.40)
2  16/1,556 0.84 (0.31–2.28) 0.98 (0.35–2.72)
3  18/1,556 0.96 (0.38–2.46) 1.13 (0.44–2.92)
Current active smoking vs. never active smoking
1  72/989 0.83 (0.47–1.47) 0.90 (0.51–1.62)
2  10/989 0.83 (0.16–4.23) 0.88 (0.17–4.57)
3  9/989 — —
Past active smoking vs. never active smoking
1  96/1,262 0.93 (0.61–1.43) 0.99 (0.64–1.52)
2  14/1,262 0.96 (0.32–2.86) 1.08 (0.36–3.30)
3  18/1,262 1.36 (0.53–3.50) 1.60 (0.61–4.18)
Both active and passive smoking vs. never passive or active smoking
1  60/875 0.65 (0.36–1.17) 0.69 (0.37–1.27)
2  8/875 0.72 (0.14–3.71) 0.87 (0.17–4.61)
3  9/875 — —
Active smoking only vs. never passive or active smoking
1  33/328 1.14 (0.53–2.42) 1.23 (0.57–2.66)
2  4/328 1.39 (0.19–10.31) 1.50 (0.20–11.38)
3  0/328 — —
Ever passive smoking only vs. never passive or active smoking
1  54/681 0.78 (0.42–1.42) 0.81 (0.44–1.49)
2  8/681 1.71 (0.32–9.21) 1.73 (0.32–9.38)
3  9/681 — —
Ever passively exposed to spouse vs. never passively exposed to spouse
1  80/1,228 1.50 (0.92–2.46) 1.51 (0.92–2.46)
2  12/1,228 2.15 (0.61–7.56) 2.21 (0.63–7.70)
3  18/1,228 3.36 (0.94–12.04) 3.23 (0.90–11.57)
Lifetime intake of smoked/grilled meat (high vs. low)b
1  110/1,475 0.98 (0.66–1.46) 0.98 (0.66–1.46)
2  16/1,475 3.64 (1.12–11.79) 3.64 (1.12–11.79)
3  18/1,475 1.16 (0.45–2.99) 1.16 (0.45–2.99)
Total B[a]Ps from meat (high intake vs. low intake)c
1  109/1,475 1.17 (0.79–1.74) 1.17 (0.79–1.74)
2  16/1,475 1.79 (0.64–5.04) 1.79 (0.64–5.04)
3  18/1,475 8.04 (2.29–28.27) 8.04 (2.29–28.27)
—, insufficient sample size.
aIn addition to adjustment for age group, final models were adjusted for daily alcohol intake when examining smoking 
exposure and age at menarche when examining PAH–DNA adducts. bLifetime intake of grilled and smoked meat is 
dichotomized based on median lifetime servings among controls (median, 4,160 servings). cDaily intake of B[a]Ps from 
meat is dichotomized based on median daily intake among controls (median, 0.42 ng/day).PAH, p53 mutations, and breast cancer risk
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A number of studies found results similar 
to ours when examining associations between 
PAH-related sources and p53 mutations in 
smoking-related cancers (Diergaarde et al. 
2003; Fryzek et al. 2006; Harty et al. 1996; 
Schroeder et al. 2003; Zhang et al. 2006). 
Most studies that examined p53 mutational 
spectra found a difference in spectrum by 
exposure status, despite null or inverse associa-
tions with p53 mutation prevalence, possibly 
because associations with specific mutation 
patterns were washed out when all mutations 
were combined into a single case subgroup. 
For example, a study by Schroeder et al. 
(2003) that observed no difference in p53 
mutation frequency in bladder cancer accord-
ing to smoking status found that smoking 
was strongly associated with CpG G:C→A:T 
transitions. 
The main limitation of our study is the 
sample size for examining subgroup mutation 
effects, for example, by type or number. Some 
of our point estimates have very wide CI esti-
mates, and these results should be interpreted 
with caution. We cannot rule out that our 
findings are due to chance. However, this is 
the largest study regarding PAH-related expo-
sures and breast tumor p53 mutations con-
ducted to date, and the first study to look at 
associations for most of the PAH-related expo-
sures examined in this investigation. Thus, 
we believe that our analysis is an important 
addition to the sparse literature for this topic. 
The strengthened associations observed after 
minimizing PAH exposure in referent groups 
provide further support for a relation between 
PAHs and breast cancer p53 mutation status, 
type, and effect.
A potential limitation in any retrospec-
tive, case–control analysis is the possibility 
of recall bias. However, cases were unaware 
of the mutation patterns in their tumor tis-
sue, so this potential bias is less likely to affect 
case–case comparisons. Many of the exposure 
variables examined were surrogates of PAH 
exposure, although PAH–DNA adducts are 
an internal measure of PAH exposure and 
response (Gammon and Santella 2008). 
However, PAH–DNA adducts reflect only 
recent exposures, whereas exposures in the 
more distant past are likely to be relevant to 
carcinogenesis. Evaluation of exons 5–8 only 
is likely to under  estimate the prevalence of 
p53 mutations. However, these exons contain 
> 90% of mutations reported in breast can-
cer (Lacroix et al. 2006). Missense mutations 
are concentrated in the central part of p53, 
whereas nonsense, silent, and frameshift muta-
tions are distributed throughout the coding 
region (Greenblatt et al. 1994).
Previous research has suggested that associa-
tions between PAHs and p53 mutation pattern 
may vary by genetic variants for detoxi  fication 
and DNA repair enzymes (Biggs et al. 1993; 
Schroeder et al. 2003; Van Emburgh et al. 
2008) and that the carcinogenic effects of PAHs 
on the breast may be stronger among women 
with low anti  oxidant intake (Steck et al. 2007). 
Therefore, future high-powered analyses should 
examine effect modification by genotypes rele-
vant to detoxification, anti  oxidative response, 
and DNA repair and by anti  oxidant intake. 
Future studies should also categorize exposures 
more finely and should assess the importance of 
timing of PAH exposure on p53 mutagenesis.
Conclusions
Our findings suggest that PAH exposures may 
be associated with breast tumor p53 muta-
tion effect, type, and number rather than 
with overall p53 mutations, and may also be 
related to breast cancer through mechanisms 
other than p53 mutation. The high incidence 
of breast cancer implies that even modestly 
increased risks for tumor subgroups may 
have substantial public health significance. 
This analysis has extended previous research 
regarding a sparsely investigated topic. Our 
results provide new information to guide 
future research regarding the carcinogenic 
effects of PAH exposure on the human breast.
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